The efficacy of edaravone for treating lacunar infarction
スポンサーリンク
概要
- 論文の詳細を見る
To estimate the efficacy of the free radical scavenger edaravone, we administered edaravone (Group A) or sodium ozagrel (Group B) for 14 days in randomly selected patients within 24 hours after the onset of lacunar infarction. The percentage of patients whose NIH Stroke Scale (NIHSS) improved by more than 2 points was 72.7% in Group A and 61.5% in Group B; the difference was not statistically significant. The percentage of patients whose modified Rankin Scale (mRS) was rated at 1 or less upon discharge was 86.4% in Group A and 57.7% in Group B; the difference was statistically significant (p<0.05). The percentage of patients whose NIHSS improved by more than 2 points during the period from 7 days up to 20 days after onset was 40.9% in Group A and 26.9% in Group B. In Group A, the NIHSS tended to improve from 7 days after onset. Edaravone needs continuous administration for more than one week in order to show a therapeutic benefit.
- 一般社団法人 日本脳卒中学会の論文
一般社団法人 日本脳卒中学会 | 論文
- Two cases with aphasia in the left putaminal damage and one case with visuospatial neglect in the right putaminal damage
- Alterations of plasma von Willebrand factor activity and the influence of anti-platelet drugs in acute cerebral infarction
- Carotid endarterectomy plaques correlation of clinical events and morphology.
- Stenting for stenosis of major cerebrovascular arteries.
- Cerebral infarction following antihypertensive therapy.